LS Investment Advisors LLC boosted its stake in Catalent Inc (NYSE:CTLT) by 22.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,261 shares of the company’s stock after purchasing an additional 2,258 shares during the quarter. LS Investment Advisors LLC’s holdings in Catalent were worth $504,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds also recently made changes to their positions in the company. 361 Capital LLC raised its stake in shares of Catalent by 18.6% during the third quarter. 361 Capital LLC now owns 70,022 shares of the company’s stock worth $2,795,000 after acquiring an additional 10,974 shares in the last quarter. Schwab Charles Investment Management Inc. raised its stake in shares of Catalent by 25.2% during the third quarter. Schwab Charles Investment Management Inc. now owns 1,046,417 shares of the company’s stock worth $41,773,000 after acquiring an additional 210,296 shares in the last quarter. Stevens Capital Management LP purchased a new position in shares of Catalent during the third quarter worth approximately $2,475,000. Sei Investments Co. raised its stake in shares of Catalent by 119.1% during the third quarter. Sei Investments Co. now owns 94,216 shares of the company’s stock worth $3,761,000 after acquiring an additional 51,212 shares in the last quarter. Finally, Emerald Mutual Fund Advisers Trust purchased a new position in shares of Catalent during the third quarter worth approximately $18,420,000. 99.82% of the stock is currently owned by institutional investors and hedge funds.
CTLT has been the topic of several research reports. Zacks Investment Research raised shares of Catalent from a “hold” rating to a “buy” rating and set a $48.00 price target on the stock in a research note on Wednesday, January 17th. Goldman Sachs Group initiated coverage on shares of Catalent in a research note on Wednesday, January 24th. They set a “buy” rating and a $50.00 price target on the stock. Royal Bank of Canada set a $48.00 price target on shares of Catalent and gave the stock a “buy” rating in a research note on Monday, February 5th. Bank of America lifted their price target on shares of Catalent from $47.00 to $49.00 and gave the stock a “buy” rating in a research note on Tuesday, February 6th. Finally, ValuEngine raised shares of Catalent from a “hold” rating to a “buy” rating in a research note on Wednesday, February 7th. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $45.60.
In other news, Director Uwe Roehrhoff bought 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, November 21st. The shares were bought at an average cost of $39.22 per share, with a total value of $294,150.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider John R. Chiminski sold 181,458 shares of Catalent stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total transaction of $7,189,365.96. The disclosure for this sale can be found here. 1.70% of the stock is owned by insiders.
Catalent Inc (CTLT) opened at $43.37 on Friday. The company has a quick ratio of 1.78, a current ratio of 2.22 and a debt-to-equity ratio of 2.66. Catalent Inc has a one year low of $27.48 and a one year high of $47.87. The company has a market cap of $5,715.37, a price-to-earnings ratio of 26.79, a P/E/G ratio of 2.46 and a beta of 1.47.
Catalent (NYSE:CTLT) last issued its earnings results on Monday, February 5th. The company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.31 by $0.10. Catalent had a net margin of 3.03% and a return on equity of 23.85%. The company had revenue of $606.30 million for the quarter, compared to the consensus estimate of $565.05 million. During the same period in the previous year, the firm earned $0.27 earnings per share. The firm’s revenue for the quarter was up 25.3% on a year-over-year basis. analysts anticipate that Catalent Inc will post 1.53 EPS for the current year.
TRADEMARK VIOLATION WARNING: “Catalent Inc (CTLT) Position Raised by LS Investment Advisors LLC” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/17/catalent-inc-ctlt-position-raised-by-ls-investment-advisors-llc.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.